While single pathway inhibition with either enzalutamide or BEZ235 (a PI3K inhibitor) only had modest cytostatic effects, the combination of AR and PI3K pathway inhibition (in particular PI3K and/or mTORC 1/2) or PI3K inhibition and HER2/3 inhibition led to significant tumor reductions. The gene discussed is AR; the disease is neoplasm.